Streetbeat News

Stock Prices

THRX

Analysts have given Theseus Pharmaceuticals (NASDAQ:THRX) mostly bullish ratings in the last quarter, with a total of 6 bullish and 2 somewhat bullish ratings. The company has an average price target of $17.0, representing a 26.09% decrease from the previous average price target of $23.00.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:01 pm

BNTX

BioNTech (NASDAQ:BNTX) has received 6 bullish and 7 indifferent ratings from analysts in the last quarter. The average price target is $148.23, representing an upside from the current price of $109.51. This average price target is a 6.33% decrease from the previous average of $158.25.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:01 pm

CLH

Analysts have provided bullish ratings for Clean Harbors (NYSE:CLH) in the last quarter, with 6 bullish, 2 somewhat bullish, and 1 indifferent. The company has an average price target of $165.44, an increase of 8.13% from the previous average price target of $153.00.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:00 pm

EPR

Over the last quarter, EPR Props (NYSE:EPR) has received 7 analyst ratings, with 1 being bullish, 3 somewhat bullish, and 3 indifferent. The average price target is $49.21, indicating an upside from the current price of $45.98. The average price target has increased by 11.84% over the past month.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:00 pm

CHUY

Over the past 3 months, 8 analysts have published their opinion on Chuy's Holdings (NASDAQ:CHUY) stock. The analysts have an average price target of $40.5 versus the current price of Chuy's Holdings at $41.36, implying a downside. The average price target has increased by 7.06% over the past month.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:00 pm

RIOT

Riot Platforms (NASDAQ:RIOT) has received positive analyst ratings in the last quarter, with 3 bullish and 2 somewhat bullish ratings. The average 12-month price target for the company is $15.9, which has increased by 34.75% over the past month.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 1:00 pm

KRTX

Karuna Therapeutics' stock has seen a 13% pullback from June 2023 highs and 25% from 52-week highs, which William Blair sees as a buying opportunity. The company is expected to file an NDA for its antipsychotic drug, KarXT, in Q3 2023. Karuna has $1.5 billion in cash to fund operations through 2026 and is considered a potential acquisition target. The company's drug belongs to a Medicare Part D protected class, ensuring automatic coverage upon approval.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 12:59 pm

PFE

RHHBY

ROIV

Roivant Sciences Ltd (ROIV), founded by Republican presidential candidate Vivek Ramaswamy, is in talks with Roche Holdings AG (RHHBY) for the potential sale of an experimental drug for stomach diseases. The deal could exceed $7 billion. The drug, RVT-3101, is currently in the final Phase 3 testing stage. Roivant obtained the drug through a deal with Pfizer Inc (PFE), which retains a 25% stake in the subsidiary and holds commercial rights outside the U.S. and Japan.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 12:55 pm

UNH

UnitedHealth Group Inc (NYSE:UNH) reported Q2 profits of nearly $5.5 billion, up 8% Y/Y, and sales of $92.9 billion, up almost 16% Y/Y, beating consensus estimates. Adjusted EPS of $6.14 increased 14% Y/Y, surpassing the consensus of $6.01. The company raised its FY23 net earnings outlook to $23.45-$23.75 per share and adjusted net earnings to $24.70-$25.00 per share. UNH shares are up 3.61% at $463.90 during premarket trading.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 12:49 pm

CGC

Canopy Growth (NASDAQ:CGC) (TSX:WEED) shares dropped 19.07% in Friday's pre-market session after the company announced a series of agreements to deleverage its balance sheet. The agreements are expected to reduce the company's total debt by approximately $437 million over the next 6 months and lower annual interest costs by $20 to $30 million. The company will also preserve approximately $92 million in cash and reduce $100 million of principal indebtedness under the credit facility.

Portfolio Pulse from Vuk Zdinjak

July 14, 2023 | 12:49 pm